Ann: OncoSil FY21 half yearly review, page-13

They are applying for reimbursements as they are applying for the ability to get products to clients, which makes good sense. While reimbursement is the icing on the cake I have a slightly different opinion then what I suspect is the common wisdom here. My reasoning is that most people in the areas targeted first like the UK, NZ and greater Europe, Australia, Singapore will have no problem coming up with 30k for a superior radiotherapy beam treatment alternative in a life or death situation which looks extremely promising at moving them to resection status, and will at worst make their final time more comfortable than the alternative options. The problem with this company currently and one which is about to be remedied with the amount of manpower thrown at it is being authorised to sell and then make people and doctors aware of the option. The product itself is likely to be highly price inelastic. Though as I mentioned others might see this differently.